glp 1 and kidney transplant glp-1 outcomes news today Receptor Agonist Use in Recipients in: Kidney Volume 17 Issue 8 (2025) GLP-1 receptor agonist versus DPP-4 – Economic evaluation of weight loss

H2Tab Hydrogen Tablets Effervescent tablets that release molecular hydrogen

In the perspective, the team noted that the GLP-1RA class of medications is transforming the care of obesity and type 2 diabetes in adults and noted recent studies indicating similar powerful effects in children and adolescents

Diabetes Spend Is Growing 4 Slower Than Non-Diabetic Costs: What the Data Shows The financial data shows an unmistakable shift: Annual spend for diabetics increased just 11% from 2021-2024 , while spend for non-diabetics jumped 15% Average monthly medical spend for diabetics decreased slightly (0.5%) , while non-diabetic medical spend surged 17% Prescription growth for diabetics (34%) stayed well below the 57% spike for non-diabetics For the first time, diabetic spend is flattening faster than non-diabetic spendcompletely reversing the previous pattern where diabetes costs outpaced everything else by 2x

For example, in the SURMOUNT-4 trial, tirzepatide discontinuers were randomized to a placebo, and they were unaware whether they were receiving tirzepatide or not. In real-world settings, the most common reasons for discontinuation are cost or insurance-related issues, and side effects, with the former predominating, he added